MicroPort Scientific Corp. (MCRPF)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 649 | 779 | 841 | 951 | 1,035 | 996 | 996 | 1,184 |
| Operating profit | $m | -53 | -37 | ||||||
| Net profit | $m | -191 | -276 | -437 | -478 | -215 | 49 | 49 | 98 |
| EPS reported | $ | 0.03 | 0.02 | ||||||
| Operating cashflow per share | $ | 0.00 | 0.03 | ||||||
| Capex per share | $ | 0.05 | 0.05 | ||||||
| FCF per share | $ | -0.04 | -0.02 | ||||||
| Free cash flow | $m | -78 | -77 | ||||||
| Net debt | $m | 735 | 735 | ||||||
| Book value equity | $m | 981 | 981 | ||||||
| Book value per share | $ | 0.50 | 0.51 | ||||||
| Number of shares | m | 1,966.53 | 1,912.7 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 90.79 | - | ||||||
| P/B LTM | x | 2.63 | 2.63 | ||||||
| P/S LTM | x | 2.59 | 2.59 | ||||||
| P/FCF LTM | x | -33.24 | -33.55 | ||||||
| EV/EBITDA LTM | x | 39.42 | 35.70 | ||||||
| EV/Sales LTM | x | 3.51 | 2.59 | ||||||
| Earnings Yield LTM | % | +1.10% | +3.39% | ||||||
| FCF Yield | % | -3.01% | -2.98% | ||||||
| Quality | |||||||||
| ROE | % | +4.95% | +6.07% | ||||||
| ROIC | % | -1.65% | -1.15% | ||||||
| Operating margin | % | -5.31% | -3.73% | ||||||
| Gross margin | % | +55.63% | +55.18% | ||||||
| FCF/Sales | % | -7.80% | -4.07% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -3.76% | -3.82% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.05 | -0.05 | ||||||
| Net Debt/EBITDA | x | 10.34 | 11.59 | ||||||
| EBIT/Net interest | x | -0.48 | -0.37 | ||||||
| Net debt/market cap | % | +59.96% | +93.11% | ||||||
| Net debt/Equity | x | 0.75 | 0.75 | ||||||
| Gross debt/equity | x | 1.63 | 1.63 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
MicroPort Scientific Corp. is an investment holding company, which engages in the research and development, manufacture, and distribution of medical devices. It operates through the following segments: Cardiovascular Devices Business, Orthopedics Devices Business, Cardiac Rhythm Management Business, Endovascular and Peripheral Vascular Devices Business, Neurovascular Devices Business, Surgical Devices Business, Heart Valve Business, Surgical Robot Devices Business, and Others. The Cardiovascular Devices Business segment offers integrated medical solutions for the treatment of coronary artery-related diseases, develops, manufactures, and commercializes coronary stents and related delivery systems, along with balloon catheters, passive accessories and active devices, in fulfilling the overall demands of doctors and patients worldwide. The Orthopedics Devices Business segment is involved in the total solutions for the treatment of orthopedic problems, with an extensive range of orthopedics products that include reconstructive joints, spine and trauma products, and other professional implants and instruments. The Cardiac Rhythm Management Business segment develops, manufactures, and markets of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, with products covering pacemakers, defibrillators, and cardiac resynchronization therapy devices. The Endovascular and Peripheral Vascular Devices Business segment focuses on providing integrated disease solutions for aortic and peripheral vascular diseases such as thoracic and abdominal aortic aneurysm, aortic dissection, atherosclerosis, and lower extremity arteriosclerotic occlusion. The Neurovascular Devices Business segment specializes in providing total solutions for the treatment of neurovascular diseases, including hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke, continuously focused on research and development, production and commercialization of neurovascular therapeutic and access devices. The Surgical Devices Business segment provides overall solutions for cardiac surgery and emergency life support. The Heart Valve Business segment includes sale, manufacture, research, and development of heart valve devices. The Surgical Robot Devices Business segment designs, develops, and commercializes innovative surgical robots. The company was founded by Zhao Hua Chang in 1998 and is headquartered in Shanghai, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
MicroPort Scientific Corp. is an investment holding company, which engages in the research and development, manufacture, and distribution of medical devices. It operates through the following segments: Cardiovascular Devices Business, Orthopedics Devices Business, Cardiac Rhythm Management Business, Endovascular and Peripheral Vascular Devices Business, Neurovascular Devices Business, Surgical Devices Business, Heart Valve Business, Surgical Robot Devices Business, and Others. The Cardiovascular Devices Business segment offers integrated medical solutions for the treatment of coronary artery-related diseases, develops, manufactures, and commercializes coronary stents and related delivery systems, along with balloon catheters, passive accessories and active devices, in fulfilling the overall demands of doctors and patients worldwide. The Orthopedics Devices Business segment is involved in the total solutions for the treatment of orthopedic problems, with an extensive range of orthopedics products that include reconstructive joints, spine and trauma products, and other professional implants and instruments. The Cardiac Rhythm Management Business segment develops, manufactures, and markets of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, with products covering pacemakers, defibrillators, and cardiac resynchronization therapy devices. The Endovascular and Peripheral Vascular Devices Business segment focuses on providing integrated disease solutions for aortic and peripheral vascular diseases such as thoracic and abdominal aortic aneurysm, aortic dissection, atherosclerosis, and lower extremity arteriosclerotic occlusion. The Neurovascular Devices Business segment specializes in providing total solutions for the treatment of neurovascular diseases, including hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke, continuously focused on research and development, production and commercialization of neurovascular therapeutic and access devices. The Surgical Devices Business segment provides overall solutions for cardiac surgery and emergency life support. The Heart Valve Business segment includes sale, manufacture, research, and development of heart valve devices. The Surgical Robot Devices Business segment designs, develops, and commercializes innovative surgical robots. The company was founded by Zhao Hua Chang in 1998 and is headquartered in Shanghai, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free